Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook

Novo Nordisk (NYSE:NVO), a diabetes and obesity drug maker, closed Tuesday at $50.33, down 14.59%. The stock sold off after management projected a 2026 sales and profit decline despite strong recent results, and investors are watching how it defends U.S. obesity-drug share and pricing. The company’s trading volume reached 67.7 million shares, which is about 218% above its three-month average of 21.3 million shares. Novo Nordisk went public in 1981 and has grown more than 3,1000% since its IPO.S&P 500 (SNPINDEX: ^GSPC) slipped 0.85% to 6,917, while the Nasdaq Composite (NASDAQINDEX: ^IXIC) fell 1.43% to 23,255 as growth stocks lost ground. Among pharmaceuticals peers, Eli Lilly (NYSE:LLY) closed at $1,002.98, down 3.94%, while Novartis (NYSE:NVS) finished at $149.86, off 0.78%, reflecting broader pressure across large drugmakers.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool